

In the Specification:

Please amend the paragraph at page 1, lines 3-10 as follows:

This application is a continuation-in-part of U.S.S.N. 08/631,469, filed April 12, 1996, now U.S. Patent No. 6,221,840, which is a continuation-in-part of U.S.S.N. 08/191,352, filed February 2, 1994, now abandoned, which is a continuation of U.S.S.N. 08/037,741, filed March 25, 1993, now abandoned, which is a continuation of U.S.S.N. 07/837,192, filed February 13, 1992, now abandoned, which is a continuation-in-part of U.S.S.N. 07/655,965, filed February 14, 1991, now abandoned.

In the Claims:

Please amend claims 1, 5, 7, and 9-11 as follows:

1. (Amended) A method for the treatment of an eye disorder in a patient, said disorder characterized by an injury to the corneal epithelial, said method comprising administering to said patient a trefoil protein, or a biologically active fragment thereof.

5. (Amended) The method of claim 2, wherein said trefoil protein is pS2.

7. (Amended) A method for the treatment of a lesion of the corneal epithelium in a patient, said method comprising administering to said patient a trefoil peptide, or a biologically active fragment thereof.

9. (Amended) The method of claim 7, wherein said trefoil peptide is intestinal trefoil factor (ITF).